Fortress Biotech, Inc.
About Fortress Biotech, Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $63.3M
- Net income
- $6.8M
- Total assets
- $185.5M
- Market cap
- $88.0M
- Gross margin
- 66.9%
- Operating margin
- -111.0%
- Net margin
- -52.0%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $63.3M
- Cost of revenue
- $20.9M
- Gross profit
- $42.3M
- Operating expenses
- $112.6M
- Operating income
- -$70.2M
- Income tax
- -$620.0K
- Net income
- -$32.9M
- EPS (basic)
- $-0.07
- EPS (diluted)
- $-0.07
Balance sheet
- Total assets
- $185.5M
- Current assets
- $123.8M
- Total liabilities
- $123.4M
- Current liabilities
- $49.7M
- Shareholders’ equity
- $62.2M
Cash flow
- Operating cash flow
- -$65.8M
- Investing cash flow
- $10.1M
- Financing cash flow
- $77.4M
- Net cash flow
- $21.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $88.0M
- EPS (diluted)
- $-0.07
- Shares outstanding
- 30.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 17, 2011
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $6.8M in FY2025.
- Revenue declined 8% from FY2021 to FY2025.
- Gross margin of 66.9%, net margin -52.0%.
- Trading 35% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Fortress Biotech, Inc..
Write a review
News about Fortress Biotech, Inc.
News & sentiment via Polygon.io
